Within the past decade, newer salvage combination chemotherapy regimens have been
studied for relapsed or refractory HL, and have been shown to induce significant responses …

The management of relapsed or refractory Hodgkin's lymphoma (RR-HL) remains a
challenge for hematologists and oncologists. Salvage chemotherapy followed by autologous …

Primary therapy for Hodgkin lymphoma (HL) is curative in∼ 85% of patients [1].
Randomized phase III and single arm phase II trials have established high dose …

Hodgkin lymphoma is a highly curable malignancy, with an excellent prognosis. However,
around 10% to 25% of patients will have primary refractory or relapsed disease, despite …

Relapsed/Refractory Hodgkin Lymphoma - Hematology/Oncology Clinics Skip to Main
Content Advertisement Hematology/Oncology Clinics Log in Register Log in Subscribe Claim …

Background: Treatment strategies for patients (pts) with relapsed/refractory (RR) classical
Hodgkin lymphoma (cHL) continue to evolve as brentuximab vedotin (BV) and immune …

Introduction: Limited information exists on the best treatment strategy for Primary Refractory
(ref) Hodgkin Lymphoma (HL). For the past 20 years, we have treated patients (pts) on …

Hodgkin lymphoma (HL) is curable in 70–80% of patients with first-line therapy. However,
relapses occur in a minority of patients with favorable early stage disease and are more …

Introduction: The management of classical Hodgkin lymphoma (cHL) with first line therapy
continues to evolve resulting in some of the best outcomes in oncology. Around 20-30% of …

Patients with relapsed/refractory Hodgkin lymphoma (RR‐HL) who progress or relapse
following autologous stem cell transplantation (ASCT) have historically had a poor …